Biographical Sketch
William Fissell, MD, has degrees in physics and electrical engineering from M.I.T., and he went on to apply his engineering training to treatment of patients with kidney disease first at Case Western Reserve University, University Hospitals of Cleveland, and the Louis B. Stokes Cleveland VA, where he completed medical school and residency.
Dr. Fissell moved to University of Michigan, Ann Arbor, for his fellowship in nephrology, where he trained with H. David Humes, pioneer of the first bioartificial kidney in clinical trials. He stayed at University of Michigan for his first two faculty appointments before moving to the Cleveland Clinic in 2007.
He has pioneered the application of silicon nanotechnology to hemodialysis and hemofiltration, and presently directs the Renal Nanotechnology Laboratory and the Innovations Center for Extracorporeal Therapy at Cleveland Clinic.
Dr. Fissell's clinical practice focuses on the care of critically ill patients with renal disease.
Specialty Interests
critical care nephrology, dialysis and hemofiltration membrane technology, novel therapies in treatment of ESRD, Dialysis, hemofiltration membrane technology
Innovations & Patents
Dr. Fissell is among the inventors of a pioneering new membrane technology, patented in 2005. These membranes allow miniaturization of dialysis devices, and, someday, implantable dialysis devices.
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 8/4/2008, Dr.
Fissell has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Fissell receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
Gambro Renal Products
